{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T16:04:17Z","timestamp":1783353857482,"version":"3.54.6"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,13]],"date-time":"2025-07-13T00:00:00Z","timestamp":1752364800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,13]],"date-time":"2025-07-13T00:00:00Z","timestamp":1752364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s12012-025-10038-y","type":"journal-article","created":{"date-parts":[[2025,7,13]],"date-time":"2025-07-13T04:11:43Z","timestamp":1752379903000},"page":"1381-1410","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immunotherapy-Induced Cardiotoxicity: A Narrative Review of Real-World Case Reports, Recent Information and Clinical Evidence"],"prefix":"10.1007","volume":"25","author":[{"given":"Kayode E.","family":"Ogunniyi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trie Arni","family":"Djunadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwadabira","family":"Adewara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Babawale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olumide Damilola","family":"Akinmoju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Olamiposi","family":"Olaiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bright","family":"Nwatamole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salar","family":"Shazad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruvesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakeem Adegboyega","family":"Popoola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Onaolapo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakirat","family":"Gold-Olufadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikponmwosa Jude","family":"Ogieuhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Nfonoyim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,13]]},"reference":[{"key":"10038_CR1","doi-asserted-by":"publisher","unstructured":"Zamorano, J. L., Lancellotti, P., Rodriguez Mu\u00f1oz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., Lopez Fernandez, T., Mohty, D., Piepoli, M. F., Tamargo, J., Torbicki, A., Suter, T. M., & ESC Scientific Document Group. (2016). 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). European Heart Journal, 37(36), 2768\u20132801. https:\/\/doi.org\/10.1093\/eurheartj\/ehw211","DOI":"10.1093\/eurheartj\/ehw211"},{"issue":"15","key":"10038_CR2","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1056\/NEJMra1100265","volume":"375","author":"JJ Moslehi","year":"2016","unstructured":"Moslehi, J. J. (2016). Cardiovascular toxic effects of targeted cancer therapies. The New England Journal of Medicine, 375(15), 1457\u20131467. https:\/\/doi.org\/10.1056\/NEJMra1100265. PMID: 27732808.","journal-title":"The New England Journal of Medicine"},{"key":"10038_CR3","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"AR Lyon","year":"2020","unstructured":"Lyon, A. R., Dent, S., Stanway, S., Earl, H., Brezden-Masley, C., Cohen-Solal, A., Tocchetti, C. G., Moslehi, J. J., Groarke, J. D., Bergler-Klein, J., Khoo, V., Tan, L. L., Anker, M. S., von Haehling, S., Maack, C., Pudil, R., Barac, A., Thavendiranathan, P., Ky, B., \u2026 Lenihan, D. (2020). Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. European Journal of Heart Failure, 22, 1945\u20131960. https:\/\/doi.org\/10.1002\/ejhf.1920","journal-title":"European Journal of Heart Failure"},{"issue":"5","key":"10038_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2019.08.002","volume":"35","author":"M Abbott","year":"2019","unstructured":"Abbott, M., & Ustoyev, Y. (2019). Cancer and the immune system: The history and background of immunotherapy. Seminars in Oncology Nursing, 35(5), Article 150923. https:\/\/doi.org\/10.1016\/j.soncn.2019.08.002","journal-title":"Seminars in Oncology Nursing"},{"issue":"5 Suppl","key":"10038_CR5","doi-asserted-by":"publisher","first-page":"670","DOI":"10.6004\/jnccn.2015.0199","volume":"13","author":"AJ Olszanski","year":"2015","unstructured":"Olszanski, A. J. (2015). Principles of immunotherapy. Journal of the National Comprehensive Cancer Network, 13(5 Suppl), 670\u2013672. https:\/\/doi.org\/10.6004\/jnccn.2015.0199","journal-title":"Journal of the National Comprehensive Cancer Network"},{"key":"10038_CR6","doi-asserted-by":"publisher","first-page":"1212476","DOI":"10.3389\/fimmu.2023.1212476","volume":"14","author":"R Rui","year":"2023","unstructured":"Rui, R., Zhou, L., & He, S. (2023). Cancer immunotherapies: Advances and bottlenecks. Frontiers in Immunology, 14, 1212476. https:\/\/doi.org\/10.3389\/fimmu.2023.1212476","journal-title":"Frontiers in Immunology"},{"issue":"11","key":"10038_CR7","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002). Cancer immunoediting: From immunosurveillance to tumor escape. Nature immunology., 3(11), 991\u2013998. https:\/\/doi.org\/10.1038\/ni1102-991","journal-title":"Nature immunology."},{"issue":"10","key":"10038_CR8","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.annonc.2021.07.007","volume":"32","author":"S Loi","year":"2021","unstructured":"Loi, S., Michiels, S., Adams, S., Loibl, S., Budczies, J., Denkert, C., & Salgado, R. (2021). The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: Clinical utility in an era of checkpoint inhibition. Annals of Oncology, 32(10), 1236\u20131244. https:\/\/doi.org\/10.1016\/j.annonc.2021.07.007","journal-title":"Annals of Oncology"},{"issue":"18","key":"10038_CR9","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., & Moslehi, J. J. (2016). Fulminant myocarditis with combination immune checkpoint blockade. The New England Journal of Medicine, 375(18), 1749\u20131755. https:\/\/doi.org\/10.1056\/NEJMoa1609214","journal-title":"The New England Journal of Medicine"},{"issue":"Supplement 1","key":"10038_CR10","doi-asserted-by":"publisher","first-page":"6933","DOI":"10.1182\/blood-2023-181968","volume":"142","author":"K Ports","year":"2023","unstructured":"Ports, K., Jain, R., Diamond, S., Aptekar, J., & Fajgenbaum, D. C. (2023). Immune checkpoint inhibitors and the risk of cardiovascular adverse events: A pooled clinical trial database analysis. Blood, 142(Supplement 1), 6933. https:\/\/doi.org\/10.1182\/blood-2023-181968","journal-title":"Blood"},{"key":"10038_CR11","doi-asserted-by":"publisher","first-page":"1350585","DOI":"10.3389\/fcvm.2024.1350585","volume":"11","author":"G Murtagh","year":"2024","unstructured":"Murtagh, G., deFilippi, C., Zhao, Q., & Barac, A. (2024). Circulating biomarkers in the diagnosis and prognosis of immune checkpoint inhibitor-related myocarditis: Time for a risk-based approach. Front Cardiovasc Med., 11, 1350585. https:\/\/doi.org\/10.3389\/fcvm.2024.1350585","journal-title":"Front Cardiovasc Med."},{"issue":"2","key":"10038_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-237217","volume":"14","author":"K Oldfield","year":"2021","unstructured":"Oldfield, K., Jayasinghe, R., Niranjan, S., & Chadha, S. (2021). Immune checkpoint inhibitor-induced takotsubo syndrome and diabetic ketoacidosis: Rare reactions. BMJ Case Reports CP., 14(2), Article e237217. https:\/\/doi.org\/10.1136\/bcr-2020-237217","journal-title":"BMJ Case Reports CP."},{"issue":"13_Supplement","key":"10038_CR13","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1016\/S0735-1097(24)06351-4","volume":"83","author":"RAM Kalathil","year":"2024","unstructured":"Kalathil, R. A. M., Ahmed, H., Palicherla, A., & Aboeata, A. S. A. (2024). Pembrolizumab induced myocarditis disguised as acute coronary syndrome. Journal of the American College of Cardiology., 83(13_Supplement), 4361\u20134361. https:\/\/doi.org\/10.1016\/S0735-1097(24)06351-4","journal-title":"Journal of the American College of Cardiology."},{"issue":"5","key":"10038_CR14","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jaccao.2022.09.004","volume":"4","author":"AT Nguyen","year":"2022","unstructured":"Nguyen, A. T., Berry, G. J., Witteles, R. M., Le, D. T., Wu, S. M., Fisher, G. A., & Zhu, H. (2022). Late-onset immunotherapy-induced myocarditis 2 years after checkpoint inhibitor initiation. JACC: CardioOncology, 4(5), 727\u2013730. https:\/\/doi.org\/10.1016\/j.jaccao.2022.09.004","journal-title":"JACC: CardioOncology"},{"issue":"1","key":"10038_CR15","doi-asserted-by":"publisher","first-page":"5399073","DOI":"10.1155\/2024\/5399073","volume":"2024","author":"N Aggarwal","year":"2024","unstructured":"Aggarwal, N., Bianchini, D., Parkar, R., & Turner, J. (2024). Immunotherapy-induced overlap syndrome: Myositis, myasthenia gravis, and myocarditis\u2014a case series. Case Reports in Medicine, 2024(1), 5399073. https:\/\/doi.org\/10.1155\/2024\/5399073","journal-title":"Case Reports in Medicine"},{"key":"10038_CR16","doi-asserted-by":"publisher","first-page":"950801","DOI":"10.3389\/fmed.2022.950801","volume":"9","author":"B Yin","year":"2022","unstructured":"Yin, B., Xiao, J., Wang, X., Li, X., Guan, Y., Chen, J., Han, P., Li, K., & Wang, J. (2022). Myocarditis and myositis\/myasthenia gravis overlap syndrome induced by immune checkpoint inhibitor followed by esophageal hiatal hernia: A case report and review of the literature. Frontiers in Medicine, 9, 950801. https:\/\/doi.org\/10.3389\/fmed.2022.950801","journal-title":"Frontiers in Medicine"},{"key":"10038_CR17","doi-asserted-by":"publisher","first-page":"1336609","DOI":"10.3389\/fcvm.2024.1336609","volume":"11","author":"Y Wang","year":"2024","unstructured":"Wang, Y., Qian, M., Jin, X., Wang, J., Chen, T., Gao, P., Cheng, Z., Lai, J., Liu, Y., Fan, J., Zhang, L., Cheng, K., Deng, H., Fang, Q., & Yang, D. (2024). Case report: Temporary pacing using active fixation lead and invasive electrophysiology studies for immune checkpoint inhibitor associated reversible advanced atrioventricular block. Frontiers in Cardiovascular Medicine, 11, 1336609. https:\/\/doi.org\/10.3389\/fcvm.2024.1336609","journal-title":"Frontiers in Cardiovascular Medicine"},{"key":"10038_CR18","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s13256-021-02858-7","volume":"15","author":"J Cham","year":"2021","unstructured":"Cham, J., Ng, D., & Nicholson, L. (2021). Durvalumab-induced myocarditis, myositis, and myasthenia gravis: A case report. Journal of Medical Case Report, 15, 278. https:\/\/doi.org\/10.1186\/s13256-021-02858-7","journal-title":"Journal of Medical Case Report"},{"issue":"6","key":"10038_CR19","doi-asserted-by":"publisher","first-page":"A395","DOI":"10.1016\/j.chest.2021.12.425","volume":"161","author":"T Mccann","year":"2022","unstructured":"Mccann, T., Elabd, H., & Beerman, S. (2022). Dilated cardiomyopathy associated with immune checkpoint inhibitor, nivolumab. Chest, 161(6), A395. https:\/\/doi.org\/10.1016\/j.chest.2021.12.425","journal-title":"Chest"},{"key":"10038_CR20","doi-asserted-by":"publisher","first-page":"S1131","DOI":"10.1016\/j.annonc.2023.09.963","volume":"34","author":"A Chapman","year":"2023","unstructured":"Chapman, A., Johnson, A., Hegazy, F., Garbutt, N., Dobson, R., & Olsson-Brown, A. C. (2023). 2183P The relevance of HFpEF in immunotherapy-induced myocarditis: An analysis of 65 patients. Annals of Oncology., 34, S1131. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.963","journal-title":"Annals of Oncology."},{"issue":"5","key":"10038_CR21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.8093","volume":"12","author":"A Al-Obaidi","year":"2020","unstructured":"Al-Obaidi, A., Parker, N. A., Choucair, K., Alderson, J., & Deutsch, J. M. (2020). A case of acute heart failure following immunotherapy for metastatic lung cancer. Cureus., 12(5), Article e8093. https:\/\/doi.org\/10.7759\/cureus.8093","journal-title":"Cureus."},{"issue":"6","key":"10038_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e16874","volume":"9","author":"S Zheng","year":"2023","unstructured":"Zheng, S., Zhang, H., Hu, B., Zhou, J., Wen, L., & Li, M. (2023). A case of acute myocarditis induced by PD-1 inhibitor (sintilimab) in the treatment of large cell neuroendocrine carcinoma. Heliyon., 9(6), Article e16874. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e16874","journal-title":"Heliyon."},{"key":"10038_CR23","doi-asserted-by":"publisher","unstructured":"Escudier, M., Cautela, J., Malissen, N., Ancedy, Y., Orabona, M., Pinto, J., Monestier, S., Grob, J. J., Scemama, U., Jacquier, A., Lalevee, N., Barraud, J., Peyrol, M., Laine, M., Bonello, L., Paganelli, F., Cohen, A., Barlesi, F., Ederhy, S., & Thuny, F. (2017). Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation, 136(21), 2085\u20132087. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.030571","DOI":"10.1161\/CIRCULATIONAHA.117.030571"},{"key":"10038_CR24","doi-asserted-by":"publisher","unstructured":"Yokota, H., Asahi, R., Akamine, Y., Kobayashi, M., Wakabayashi, H., Sakamoto, S., Okuda, Y., Sato, K., Nakayama, K., & Kikuchi, M. (2024). Case report of QT interval prolongation induced by anamorelin in an obese patient with non-small cell lung cancer. Journal of Pharmaceutical Health Care and Sciences, 10, 33. https:\/\/doi.org\/10.1186\/s40780-024-00338-5","DOI":"10.1186\/s40780-024-00338-5"},{"issue":"1","key":"10038_CR25","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.cardfail.2023.10.055","volume":"30","author":"AS Mueller","year":"2024","unstructured":"Mueller, A. S., & Correa, A. (2024). Checkpoint immunotherapy-induced myocarditis requiringmechanical circularly support: A case report and future outlook. Journal of Cardiac Failure., 30(1), 138. https:\/\/doi.org\/10.1016\/j.cardfail.2023.10.055","journal-title":"Journal of Cardiac Failure."},{"issue":"6","key":"10038_CR26","first-page":"383","volume":"42","author":"J Zhang","year":"2021","unstructured":"Zhang, J., Li, J., Zhai, L., & Lin, L. (2021). Coexisting of myasthenia gravis and fulminant myocarditis induced by nivolumab in a patient with ureteral epithelial cancer. Neuro Endocrinology Letters, 42(6), 383\u2013386.","journal-title":"Neuro Endocrinology Letters"},{"key":"10038_CR27","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ejca.2018.06.021","volume":"101","author":"AM Berner","year":"2018","unstructured":"Berner, A. M., Sharma, A., Agarwal, S., Al-Sam, S., & Nathan, P. (2018). Fatal autoimmune myocarditis with anti-PD-L1 and tyrosine kinase inhibitor therapy for renal cell cancer. European Journal of Cancer, 101, 287\u2013290. https:\/\/doi.org\/10.1016\/j.ejca.2018.06.021","journal-title":"European Journal of Cancer"},{"key":"10038_CR28","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3892\/etm.2024.12622","volume":"28","author":"Y Li","year":"2024","unstructured":"Li, Y., Zhai, B., Yang, B., Wang, B., Wang, Y., Qu, M., & Tang, Y. (2024). Immune myocarditis induced by sintilimab therapy: A case report. Experimental and Therapeutic Medicine, 28, 333.","journal-title":"Experimental and Therapeutic Medicine"},{"key":"10038_CR29","doi-asserted-by":"publisher","first-page":"682262","DOI":"10.3389\/fimmu.2021.682262","volume":"12","author":"S Liang","year":"2021","unstructured":"Liang, S., Yang, J., Lin, Y., Li, T., Zhao, W., Zhao, J., & Dong, C. (2021). Immune myocarditis overlapping with myasthenia gravis due to anti\u2013PD-1 treatment for a chordoma patient: A case report and literature review. Frontiers in Immunology, 12, 682262. https:\/\/doi.org\/10.3389\/fimmu.2021.682262","journal-title":"Frontiers in Immunology"},{"key":"10038_CR30","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.2147\/OTT.S333242","volume":"14","author":"Y Li","year":"2021","unstructured":"Li, Y., Hu, Y., Yang, B., Jin, C., Ren, H., Wu, J., Wang, Z., Wei, Y., Yang, L., & Hu, Y. (2021). Immunotherapy-related cardiotoxicity re-emergence in non-small cell lung cancer \u2013 A case report. OncoTargets and Therapy, 14, 5309\u20135314. https:\/\/doi.org\/10.2147\/OTT.S333242","journal-title":"OncoTargets and Therapy"},{"issue":"11","key":"10038_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-244334","volume":"14","author":"C Wakefield","year":"2021","unstructured":"Wakefield, C., Shultz, C., Patel, B., & Malla, M. (2021). Life-threatening immune checkpoint inhibitor-induced myocarditis and myasthenia gravis overlap syndrome treated with abatacept: A case report. BMJ Case Reports CP., 14(11), Article e244334. https:\/\/doi.org\/10.1136\/bcr-2021-244334","journal-title":"BMJ Case Reports CP."},{"issue":"1","key":"10038_CR32","doi-asserted-by":"publisher","first-page":"yty149","DOI":"10.1093\/ehjcr\/yty149","volume":"3","author":"C Gallegos","year":"2019","unstructured":"Gallegos, C., Rottmann, D., Nguyen, V. Q., & Baldassarre, L. A. (2019). Myocarditis with checkpoint inhibitor immunotherapy: Case report of late gadolinium enhancement on cardiac magnetic resonance with pathology correlate. European Heart Journal - Case Reports., 3(1), yty149. https:\/\/doi.org\/10.1093\/ehjcr\/yty149","journal-title":"European Heart Journal - Case Reports."},{"key":"10038_CR33","doi-asserted-by":"publisher","first-page":"100839","DOI":"10.1016\/j.rmcr.2019.100839","volume":"27","author":"T Sakai","year":"2019","unstructured":"Sakai, T., Yahagi, K., Hoshino, T., Yokota, T., Tanabe, K., Mori, M., & Ikeda, S. (2019). Nivolumab-induced myocardial necrosis in a patient with lung cancer: A case report. Respiratory Medicine Case Reports, 27, 100839. https:\/\/doi.org\/10.1016\/j.rmcr.2019.100839","journal-title":"Respiratory Medicine Case Reports"},{"key":"10038_CR34","doi-asserted-by":"publisher","DOI":"10.1177\/10781552221105572","author":"L Bonhomme-Faivre","year":"2023","unstructured":"Bonhomme-Faivre, L., Guarino, V., & Misra, S. C. (2023). Nivolumab-induced pneumonitis and cardiopathy in a patient with relapsed Hodgkin\u2019s lymphoma. Journal of Oncology Pharmacy Practice. https:\/\/doi.org\/10.1177\/10781552221105572","journal-title":"Journal of Oncology Pharmacy Practice"},{"issue":"4","key":"10038_CR35","doi-asserted-by":"publisher","first-page":"A5699","DOI":"10.1016\/j.chest.2023.07.3677","volume":"164","author":"B Schutte","year":"2023","unstructured":"Schutte, B., Ray, A. S., Malesker, M. A., & Cookman, C. (2023). Pembrolizumab-induced myasthenia crisis, myocarditis, myositis, and hepatitis. Chest, 164(4), A5699. https:\/\/doi.org\/10.1016\/j.chest.2023.07.3677","journal-title":"Chest"},{"key":"10038_CR36","doi-asserted-by":"publisher","unstructured":"Cao, J., Li, Q., Zhi, X., Yang, F., Zhu, W., Zhou, T., Hou, X., & Chen, D. (2021). Pembrolizumab-induced autoimmune Stevens-Johnson syndrome\/toxic epidermal necrolysis with myositis and myocarditis in a patient with esophagogastric junction carcinoma: A case report. Translational Cancer Research, 10(8), 3870\u20133876. https:\/\/doi.org\/10.21037\/tcr-21-470","DOI":"10.21037\/tcr-21-470"},{"key":"10038_CR37","doi-asserted-by":"crossref","unstructured":"Sequential Blockade of PD-1 and PD-L1 Causes Fulminant Cardiotoxicity\u2014From Case Report to Mouse Model Validation. Accessed February 18, 2025. https:\/\/www.mdpi.com\/2072-6694\/11\/4\/580","DOI":"10.3390\/cancers11040580"},{"issue":"11","key":"10038_CR38","doi-asserted-by":"publisher","first-page":"59","DOI":"10.7759\/cureus.48859","volume":"15","author":"R Abulnaja","year":"2023","unstructured":"Abulnaja, R. (2023). Stage 4 non-small cell lung cancer with human epidermal growth factor receptor 2 alterations and myocarditis induced by immune checkpoint inhibitors: A case report. Cureus., 15(11), 59. https:\/\/doi.org\/10.7759\/cureus.48859","journal-title":"Cureus."},{"issue":"12","key":"10038_CR39","doi-asserted-by":"publisher","first-page":"100432","DOI":"10.1016\/j.jtocrr.2022.100432","volume":"3","author":"M Riudavets","year":"2022","unstructured":"Riudavets, M., Azarine, A., Smaali, S., Kim, Y. W., Thomas de Montpr\u00e9ville, V., Grecea, A. M., Naltet, C., Gazzah, A., & Planchard, D. (2022). Unexpected cardiotoxicity in patients with HER2-mutant NSCLC treated with trastuzumab deruxtecan: A case report. JTO Clinical Research Reports, 3(12), 100432. https:\/\/doi.org\/10.1016\/j.jtocrr.2022.100432","journal-title":"JTO Clinical Research Reports"},{"issue":"1","key":"10038_CR40","doi-asserted-by":"publisher","first-page":"51456","DOI":"10.7759\/cureus.51456","volume":"16","author":"A Khreisat","year":"2024","unstructured":"Khreisat, A., Bartosek, N., Amal, T., & Dalal, B. (2024). Durvalumab-induced myocarditis and dilated cardiomyopathy in a patient with non-small cell lung cancer a diagnostic conundrum. Cureus., 16(1), 51456. https:\/\/doi.org\/10.7759\/cureus.51456","journal-title":"Cureus."},{"key":"10038_CR41","unstructured":"The history and advances in cancer immunotherapy: Understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications | Cellular & Molecular Immunology. Accessed February 12, 2025. https:\/\/www.nature.com\/articles\/s41423-020-0488-6"},{"issue":"5","key":"10038_CR42","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., Xu, Y., Frohlich, M. W., & Schellhammer, P. F. (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. The New England Journal of Medicine, 363(5), 411\u2013422. https:\/\/doi.org\/10.1056\/NEJMoa1001294","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10038_CR43","doi-asserted-by":"publisher","first-page":"16","DOI":"10.21037\/cco.2018.04.04","volume":"7","author":"L Russell","year":"2018","unstructured":"Russell, L., & Peng, K. W. (2018). The emerging role of oncolytic virus therapy against cancer. Chinese Clinical Oncology, 7(2), 16. https:\/\/doi.org\/10.21037\/cco.2018.04.04","journal-title":"Chinese Clinical Oncology"},{"issue":"25","key":"10038_CR44","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RHI Andtbacka","year":"2015","unstructured":"Andtbacka, R. H. I., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K. A., Spitler, L. E., Puzanov, I., Agarwala, S. S., Milhem, M., Cranmer, L., Curti, B., Lewis, K., Ross, M., Guthrie, T., Linette, G. P., Daniels, G. A., Harrington, K., \u2026 Coffin, R. . S. . (2015). Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. Journal of Clinical Oncology, 33(25), 2780\u20132788. https:\/\/doi.org\/10.1200\/JCO.2014.58.3377","journal-title":"Journal of Clinical Oncology"},{"issue":"4770","key":"10038_CR45","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.3489291","volume":"233","author":"SA Rosenberg","year":"1986","unstructured":"Rosenberg, S. A., Spiess, P., & Lafreniere, R. (1986). A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science, 233(4770), 1318\u20131321. https:\/\/doi.org\/10.1126\/science.3489291","journal-title":"Science"},{"issue":"2","key":"10038_CR46","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008518","volume":"12","author":"A Sayed","year":"2024","unstructured":"Sayed, A., Munir, M., Ghazi, S. M., Ferdousi, M., Krishan, S., Shaaban, A., Habib, A., Kola-Kehinde, O., Ruz, P., Khan, S., Sharma, S., Meara, A., Mahmood, S., Feldman, S., Yang, E. H., Kim, J., Epperla, N., & Addison, D. (2024). Cardiovascular toxicities associated with bispecific T-cell engager therapy. Journal for Immunotherapy of Cancer, 12(2), Article e008518. https:\/\/doi.org\/10.1136\/jitc-2023-008518","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"7","key":"10038_CR47","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/d41573-024-00088-2","volume":"23","author":"A Mullard","year":"2024","unstructured":"Mullard, A. (2024). FDA approves first DLL3 \u00d7 CD3 bispecific T-cell engager for lung cancer. Nature Reviews. Drug Discovery, 23(7), 487. https:\/\/doi.org\/10.1038\/d41573-024-00088-2. PMID: 38789515.","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"10","key":"10038_CR48","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/ejhf.2289","volume":"23","author":"N Rubio-Infante","year":"2021","unstructured":"Rubio-Infante, N., Ram\u00edrez-Flores, Y. A., Castillo, E. C., Lozano, O., Garc\u00eda-Rivas, G., & Torre-Amione, G. (2021). Cardiotoxicity associated with immune checkpoint inhibitor therapy: A meta-analysis. European Journal of Heart Failure, 23(10), 1739\u20131747. https:\/\/doi.org\/10.1002\/ejhf.2289","journal-title":"European Journal of Heart Failure"},{"issue":"16","key":"10038_CR49","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood, S. S., Fradley, M. G., Cohen, J. V., Nohria, A., Reynolds, K. L., Heinzerling, L. M., Sullivan, R. J., Damrongwatanasuk, R., Chen, C. L., Gupta, D., Kirchberger, M. C., Awadalla, M., Hassan, M. Z. O., Moslehi, J. J., Shah, S. P., Ganatra, S., Thavendiranathan, P., Lawrence, D. P., Groarke, J. D., & Neilan, T. G. (2018). Myocarditis in patients treated with immune checkpoint inhibitors. Journal of the American College of Cardiology, 71(16), 1755\u20131764. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.037","journal-title":"Journal of the American College of Cardiology"},{"issue":"13","key":"10038_CR50","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1200\/JCO.18.02031","volume":"37","author":"JL Gulley","year":"2019","unstructured":"Gulley, J. L., Borre, M., Vogelzang, N. J., Ng, S., Agarwal, N., Parker, C. C., Pook, D. W., Rathenborg, P., Flaig, T. W., Carles, J., Saad, F., Shore, N. D., Chen, L., Heery, C. R., Gerritsen, W. R., Priou, F., Langkilde, N. C., Novikov, A., & Kantoff, P. W. (2019). Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. Journal of Clinical Oncology, 37(13), 1051\u20131061. https:\/\/doi.org\/10.1200\/JCO.18.02031","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10038_CR51","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jaccao.2022.07.014.PMID:36636447;PMCID:PMC9830211","volume":"4","author":"S Ganatra","year":"2022","unstructured":"Ganatra, S., Dani, S. S., Yang, E. H., Zaha, V. G., & Nohria, A. (2022). Cardiotoxicity of T-Cell antineoplastic therapies: JACC: CardioOncology Primer. JACC: CardioOncology, 4(5), 616\u2013623. https:\/\/doi.org\/10.1016\/j.jaccao.2022.07.014.PMID:36636447;PMCID:PMC9830211","journal-title":"JACC: CardioOncology"},{"key":"10038_CR52","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.intimp.2016.10.017","volume":"41","author":"B Darvishi","year":"2016","unstructured":"Darvishi, B., Farahmand, L., Jalili, N., & Majidzadeh-A, K. (2016). Blinatumomab provoked fatal heart failure. International Immunopharmacology, 41, 42\u201346. https:\/\/doi.org\/10.1016\/j.intimp.2016.10.017. Epub 2016 Oct 28 PMID: 27816725.","journal-title":"International Immunopharmacology"},{"issue":"9","key":"10038_CR53","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783.PMID:28249141;PMCID:PMC5881572","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian, H., Stein, A., G\u00f6kbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J. M., Wei, A., Dombret, H., Fo\u00e0, R., Bassan, R., Arslan, \u00d6., Sanz, M. A., Bergeron, J., Demirkan, F., Lech-Maranda, E., Rambaldi, A., Thomas, X., Horst, H. A., Br\u00fcggemann, M., \u2026 Topp, M. S. (2017). Blinatumomab versus chemotherapy for advanced acute lymphoblastic Leukemia. New England Journal of Medicine, 376(9), 836\u2013847. https:\/\/doi.org\/10.1056\/NEJMoa1609783.PMID:28249141;PMCID:PMC5881572","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10038_CR54","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11936-017-0532-8","volume":"19","author":"V Jain","year":"2017","unstructured":"Jain, V., Bahia, J., Mohebtash, M., & Barac, A. (2017). Cardiovascular complications associated with novel cancer immunotherapies. Current Treatment Options in Cardiovascular Medicine, 19(5), 36. https:\/\/doi.org\/10.1007\/s11936-017-0532-8","journal-title":"Current Treatment Options in Cardiovascular Medicine"},{"issue":"8","key":"10038_CR55","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1634\/theoncologist.2018-0130","volume":"23","author":"S Ganatra","year":"2018","unstructured":"Ganatra, S., & Neilan, T. G. (2018). Immune checkpoint inhibitor-associated myocarditis. The Oncologist, 23(8), 879\u2013886. https:\/\/doi.org\/10.1634\/theoncologist.2018-0130","journal-title":"The Oncologist"},{"key":"10038_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2019.100420","volume":"25","author":"L Michel","year":"2019","unstructured":"Michel, L., Rassaf, T., & Totzeck, M. (2019). Cardiotoxicity from immune checkpoint inhibitors. International Journal of Cardiology. Heart & vasculature., 25, Article 100420. https:\/\/doi.org\/10.1016\/j.ijcha.2019.100420","journal-title":"International Journal of Cardiology. Heart & vasculature."},{"issue":"5","key":"10038_CR57","doi-asserted-by":"publisher","first-page":"e145186","DOI":"10.1172\/JCI145186","volume":"131","author":"J Moslehi","year":"2021","unstructured":"Moslehi, J., Lichtman, A. H., Sharpe, A. H., Galluzzi, L., & Kitsis, R. N. (2021). Immune checkpoint inhibitor\u2013associated myocarditis: Manifestations and mechanisms. Journal of Clinical Investigation., 131(5), e145186. https:\/\/doi.org\/10.1172\/JCI145186","journal-title":"Journal of Clinical Investigation."},{"key":"10038_CR58","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen, A., G\u00f6del, P., Subklewe, M., Stemmler, H. J., Schl\u00f6\u00dfer, H. A., Schlaak, M., Kochanek, M., B\u00f6ll, B., & von Bergwelt-Baildon, M. S. (2018). Cytokine release syndrome. Journal for ImmunoTherapy of Cancer, 6, 56. https:\/\/doi.org\/10.1186\/s40425-018-0343-9","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"10304","key":"10038_CR59","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","volume":"398","author":"MS Carlino","year":"2021","unstructured":"Carlino, M. S., Larkin, J., & Long, G. V. (2021). Immune checkpoint inhibitors in melanoma. Lancet, 398(10304), 1002\u20131014. https:\/\/doi.org\/10.1016\/S0140-6736(21)01206-X","journal-title":"Lancet"},{"issue":"2","key":"10038_CR60","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018). Immune-related adverse events associated with immune checkpoint blockade. New England Journal of Medicine, 378(2), 158\u2013168. https:\/\/doi.org\/10.1056\/NEJMra1703481","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10038_CR61","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jaccao.2020.11.012","volume":"3","author":"L Zhang","year":"2021","unstructured":"Zhang, L., Reynolds, K. L., Lyon, A. R., Palaskas, N., & Neilan, T. G. (2021). The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity. JACC CardioOncol., 3(1), 35\u201347. https:\/\/doi.org\/10.1016\/j.jaccao.2020.11.012","journal-title":"JACC CardioOncol."},{"issue":"10","key":"10038_CR62","doi-asserted-by":"publisher","first-page":"e2437222","DOI":"10.1001\/jamanetworkopen.2024.37222","volume":"7","author":"D Koeckerling","year":"2024","unstructured":"Koeckerling, D., Reddy, R. K., Barker, J., Eichhorn, C., Divall, P., Howard, J. P., Korell, F., Schmitt, M., Dreger, P., Frey, N., & Lehmann, L. H. (2024). Cardiovascular events after chimeric antigen receptor T-cell therapy for advanced hematologic malignant neoplasms: A meta-analysis. JAMA Network Open, 7(10), e2437222. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.37222","journal-title":"JAMA Network Open"},{"key":"10038_CR63","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1186\/s40001-023-01464-1","volume":"28","author":"FYN Lessomo","year":"2023","unstructured":"Lessomo, F. Y. N., Mandizadza, O. O., Mukuka, C., & Wang, Z. Q. (2023). A comprehensive review on immune checkpoint inhibitors induced cardiotoxicity characteristics and associated factors. European Journal of Medical Research, 28, 495. https:\/\/doi.org\/10.1186\/s40001-023-01464-1","journal-title":"European Journal of Medical Research"},{"key":"10038_CR64","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40959-021-00106-x","volume":"7","author":"JC Lal","year":"2021","unstructured":"Lal, J. C., Brown, S. A., Collier, P., & Cheng, F. (2021). A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors. Cardiooncology, 7, 19. https:\/\/doi.org\/10.1186\/s40959-021-00106-x","journal-title":"Cardiooncology"},{"key":"10038_CR65","doi-asserted-by":"publisher","first-page":"1062858","DOI":"10.3389\/fcvm.2022.1062858","volume":"9","author":"M Torrente","year":"2022","unstructured":"Torrente, M., Blanco, M., Franco, F., Garitaonaindia, Y., Calvo, V., Collazo-Lorduy, A., Guti\u00e9rrez, L., S\u00e1nchez, J. C., Gonz\u00e1lez-del-Alba, A., Hern\u00e1ndez, R., M\u00e9ndez, M., Cantos, B., N\u00fa\u00f1ez, B., Sousa, P. A. C., & Provencio, M. (2022). Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors. Frontiers in Cardiovascular Medicine, 9, 1062858. https:\/\/doi.org\/10.3389\/fcvm.2022.1062858","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"10","key":"10038_CR66","doi-asserted-by":"publisher","first-page":"e032620","DOI":"10.1161\/JAHA.123.032620","volume":"13","author":"A Sharma","year":"2024","unstructured":"Sharma, A., Alexander, G., Chu, J. H., Markopoulos, A., Maloul, G., Ayub, M. T., Fidler, M. J., & Okwuosa, T. M. (2024). Immune checkpoint inhibitors and cardiotoxicity: A comparative meta-analysis of observational studies and randomized controlled trials. Journal of the American Heart Association, 13(10), e032620. https:\/\/doi.org\/10.1161\/JAHA.123.032620","journal-title":"Journal of the American Heart Association"},{"key":"10038_CR67","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1186\/s12935-022-02760-2","volume":"22","author":"XT Zhang","year":"2022","unstructured":"Zhang, X. T., Ge, N., Xiang, Z. J., & Liu, T. (2022). Immune checkpoint inhibitor-related adverse cardiac events in patients with lung cancer: A systematic review and meta-analysis. Cancer Cell International, 22, 363. https:\/\/doi.org\/10.1186\/s12935-022-02760-2","journal-title":"Cancer Cell International"},{"key":"10038_CR68","doi-asserted-by":"publisher","first-page":"bcr2014208203","DOI":"10.1136\/bcr-2014-208203","volume":"2015","author":"KH Ng","year":"2015","unstructured":"Ng, K. H., Dearden, C., & Gruber, P. (2015). Rituximab-induced Takotsubo syndrome: More cardiotoxic than it appears? Case Reports., 2015, bcr2014208203. https:\/\/doi.org\/10.1136\/bcr-2014-208203","journal-title":"Case Reports."},{"key":"10038_CR69","unstructured":"Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis and ACS. American College of Cardiology. Accessed February 13, 2025. https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2020\/10\/30\/15\/06\/http%3a%2f%2fwww.acc.org%2flatest-in-cardiology%2farticles%2f2020%2f10%2f30%2f15%2f06%2fdiagnosis-and-treatment-of-immune-checkpoint-inhibitor-associated-myocarditis-and-acs%3fform%3dMG0AV3"},{"key":"10038_CR70","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s11912-023-01416-6","volume":"25","author":"A Inno","year":"2023","unstructured":"Inno, A., Tarantini, L., Parrini, I., Spallarossa, P., Maurea, N., Bisceglia, I., Silvestris, N., Russo, A., & Gori, S. (2023). Cardiovascular effects of immune checkpoint inhibitors: More than just myocarditis. Current Oncology Reports, 25, 743\u2013751. https:\/\/doi.org\/10.1007\/s11912-023-01416-6","journal-title":"Current Oncology Reports"},{"issue":"6","key":"10038_CR71","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1161\/CIRCULATIONAHA.123.062405","volume":"148","author":"LH Lehmann","year":"2023","unstructured":"Lehmann, L. H., Heckmann, M. B., Bailly, G., Finke, D., Procureur, A., Power, J. R., Stein, F., Bretagne, M., Ederhy, S., Fenioux, C., Hamwy, O., Funck-Brentano, E., Romano, E., Pieroni, L., M\u00fcnster, J. P., Allenbach, Y., Anquetil, C., Leonard-Louis, S., Palaskas, N. L., \u2026 Salem, J. -E. (2023). Cardiomuscular biomarkers in the diagnosis and prognostication of immune checkpoint inhibitor myocarditis. Circulation, 148(6), 472\u2013487. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.062405","journal-title":"Circulation"},{"key":"10038_CR72","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11912-021-01060-0","volume":"23","author":"RP Patel","year":"2021","unstructured":"Patel, R. P., Parikh, R., Gunturu, K. S., Tariq, R. Z., Dani, S. S., Ganatra, S., & Nohria, A. (2021). Cardiotoxicity of immune checkpoint inhibitors. Current Oncology Reports, 23, 79. https:\/\/doi.org\/10.1007\/s11912-021-01060-0","journal-title":"Current Oncology Reports"},{"key":"10038_CR73","doi-asserted-by":"publisher","unstructured":"Dal\u2019bo, N., Patel, R., Parikh, R., Shah, S. P., Guha, A., Dani, S. S., & Ganatra, S. (2020). Cardiotoxicity of contemporary anticancer immunotherapy. Current Treatment Options in Cardiovascular Medicine, 22(62). https:\/\/doi.org\/10.1007\/s11936-020-00895-2","DOI":"10.1007\/s11936-020-00895-2"},{"issue":"5","key":"10038_CR74","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/cvr\/cvz026","volume":"115","author":"J-R Hu","year":"2019","unstructured":"Hu, J.-R., Florido, R., Lipson, E. J., Naidoo, J., Ardehali, R., Tocchetti, C. G., Lyon, A. R., Padera, R. F., Johnson, D. B., & Moslehi, J. (2019). Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovascular Research, 115(5), 854\u2013868. https:\/\/doi.org\/10.1093\/cvr\/cvz026","journal-title":"Cardiovascular Research"},{"issue":"24","key":"10038_CR75","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1161\/CIRCULATIONAHA.119.044703","volume":"141","author":"L Zhang","year":"2020","unstructured":"Zhang, L., Zlotoff, D. A., Awadalla, M., Mahmood, S. S., Nohria, A., Hassan, M. Z. O., Thuny, F., Zubiri, L., Chen, C. L., Sullivan, R. J., Alvi, R. M., Rokicki, A., Murphy, S. P., Jones-O\u2019Connor, M., Heinzerling, L. M., Barac, A., Forrestal, B. J., Yang, E. H., Gupta, D., \u2026 Neilan, T. G. (2020). Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis. Circulation, 141(24), 2031\u20132034. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044703","journal-title":"Circulation"},{"issue":"24","key":"10038_CR76","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","volume":"72","author":"VM Ferreira","year":"2018","unstructured":"Ferreira, V. M., Schulz-Menger, J., Holmvang, G., Kramer, C. M., Carbone, I., Sechtem, U., Kindermann, I., Gutberlet, M., Cooper, L. T., Liu, P., & Friedrich, M. G. (2018). Cardiovascular magnetic resonance in nonischemic myocardial inflammation: Expert recommendations. Journal of the American College of Cardiology, 72(24), 3158\u20133176. https:\/\/doi.org\/10.1016\/j.jacc.2018.09.072","journal-title":"Journal of the American College of Cardiology"},{"issue":"18","key":"10038_CR77","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/eurheartj\/ehaa051","volume":"41","author":"L Zhang","year":"2020","unstructured":"Zhang, L., Awadalla, M., Mahmood, S. S., Nohria, A., Hassan, M. Z. O., Thuny, F., Zlotoff, D. A., Murphy, S. P., Stone, J. R., Golden, D. L. A., Alvi, R. M., Rokicki, A., Jones-O\u2019Connor, M., Cohen, J. V., Heinzerling, L. M., Mulligan, C., Armanious, M., Barac, A., Forrestal, B. J., ... Neilan, T. G. (2020). Cardiovascular magnetic resonance in immune checkpoint inhibitor\u2013associated myocarditis. European Heart Journal, 41(18), 1733\u20131743. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa051","journal-title":"European Heart Journal"},{"issue":"5","key":"10038_CR78","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.jaccao.2022.06.008","volume":"4","author":"F Thuny","year":"2022","unstructured":"Thuny, F., Bonaca, M. P., & Cautela, J. (2022). What is the evidence of the diagnostic criteria and screening of immune checkpoint inhibitor-induced myocarditis? JACC: CardioOncology, 4(5), 624\u2013628. https:\/\/doi.org\/10.1016\/j.jaccao.2022.06.008","journal-title":"JACC: CardioOncology"},{"issue":"11","key":"10038_CR79","doi-asserted-by":"publisher","first-page":"e010633","DOI":"10.1161\/CIRCIMAGING.120.010633","volume":"13","author":"T Sato","year":"2020","unstructured":"Sato, T., Nakamori, S., Watanabe, S., Nishikawa, K., Inoue, T., Imanaka-Yoshida, K., Ishida, M., Sakuma, H., Ito, M., & Dohi, K. (2020). Monitoring of the evolution of immune checkpoint inhibitor myocarditis with cardiovascular magnetic resonance. Circulation: Cardiovascular Imaging, 13(11), e010633. https:\/\/doi.org\/10.1161\/CIRCIMAGING.120.010633. Epub 2020 Nov 6 PMID: 33153280.","journal-title":"Circulation: Cardiovascular Imaging"},{"key":"10038_CR80","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12410-023-09791-2","volume":"16","author":"MB Voigt","year":"2023","unstructured":"Voigt, M. B., Kravchenko, D., Isaak, A., Heine, A., Holderried, T. A. W., & Luetkens, J. A. (2023). Cardiovascular magnetic resonance assessment of immunotherapy cardiotoxicity. Current Cardiovascular Imaging Reports, 16, 103\u2013115. https:\/\/doi.org\/10.1007\/s12410-023-09791-2","journal-title":"Current Cardiovascular Imaging Reports"},{"issue":"1","key":"10038_CR81","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2967\/jnumed.121.262301","volume":"63","author":"C Rischpler","year":"2022","unstructured":"Rischpler, C., Rassaf, T., Umutlu, L., Herrmann, K., Schlosser, T. W., & Totzeck, M. (2022). Imaging the inflammatory response in checkpoint inhibition myocarditis. Journal of Nuclear Medicine., 63(1), 14\u201316. https:\/\/doi.org\/10.2967\/jnumed.121.262301","journal-title":"Journal of Nuclear Medicine."},{"issue":"supplement 2","key":"10038_CR82","first-page":"1710","volume":"54","author":"K Nallapareddy","year":"2013","unstructured":"Nallapareddy, K., Rao, J., Calambur, N., Mohammad, M., Reddy, K., & Chengapa, A. (2013). Cardiac FDG PET\/CT in inflammatory myocarditis. Journal of Nuclear Medicine., 54(supplement 2), 1710\u20131710.","journal-title":"Journal of Nuclear Medicine."},{"issue":"5","key":"10038_CR83","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jaccao.2022.11.005","volume":"4","author":"J Moslehi","year":"2022","unstructured":"Moslehi, J., & Salem, J. E. (2022). Immune checkpoint inhibitor myocarditis treatment strategies and future directions. JACC: CardioOncology., 4(5), 704\u2013707. https:\/\/doi.org\/10.1016\/j.jaccao.2022.11.005","journal-title":"JACC: CardioOncology."},{"key":"10038_CR84","doi-asserted-by":"publisher","unstructured":"Curigliano, G., Cardinale, D., Suter, T., Plataniotis, G., de Azambuja, E., Sandri, M. T., Criscitiello, C., Goldhirsch, A., Cipolla, C., Roila, F., & ESMO Guidelines Working Group. (2012). Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Annals of Oncology, 23(Suppl 7), vii155\u2013vii166. https:\/\/doi.org\/10.1093\/annonc\/mds293","DOI":"10.1093\/annonc\/mds293"},{"key":"10038_CR85","doi-asserted-by":"publisher","unstructured":"Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management - Curigliano - 2016 - CA: A Cancer Journal for Clinicians - Wiley Online Library. Accessed February 12, 2025. https:\/\/doi.org\/10.3322\/caac.21341","DOI":"10.3322\/caac.21341"},{"key":"10038_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114191","volume":"207","author":"AC Toublanc","year":"2024","unstructured":"Toublanc, A. C., Faure, M., Verdy, G., Rabeau, A., Houard, V., Veillon, R., Bardel, C., Vergnenegre, C., Dos Santos, P., Mazieres, J., & Zysman, M. (2024). Prospective cardiovascular events in patients with advanced thoracic cancer treated with immune checkpoint inhibitor. European Journal of Cancer, 207, Article 114191. https:\/\/doi.org\/10.1016\/j.ejca.2024.114191. Epub 2024 Jun 24 PMID: 38936104.","journal-title":"European Journal of Cancer"},{"key":"10038_CR87","doi-asserted-by":"publisher","unstructured":"Delombaerde, D., Vervloet, D., Franssen, C., Croes, L., Gremonprez, F., Prenen, H., Peeters, M., & Vulsteke, C. (2021) .Clinical implications of isolated troponinemia following immune checkpoint inhibitor therapy. ESMO Open 6(4), 100216. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100216. Epub 2021 Jul 13. PMID: 34271309; PMCID: PMC8287144.","DOI":"10.1016\/j.esmoop.2021.100216"},{"issue":"23","key":"10038_CR88","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1016\/j.jacc.2012.08.969","volume":"60","author":"LK Newby","year":"2012","unstructured":"Newby, L. K., Jesse, R. L., Babb, J. D., Christenson, R. H., De Fer, T. M., Diamond, G. A., Fesmire, F. M., Geraci, S. A., Gersh, B. J., Larsen, G. C., Kaul, S., McKay, C. R., Philippides, G. J., & Weintraub, W. S. (2012). ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: A report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents. Journal of the American College of Cardiology, 60(23), 2427\u20132463. https:\/\/doi.org\/10.1016\/j.jacc.2012.08.969. Epub 2012 Nov 12 PMID: 23154053.","journal-title":"Journal of the American College of Cardiology"},{"issue":"6","key":"10038_CR89","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002553","volume":"9","author":"I Puzanov","year":"2021","unstructured":"Puzanov, I., Subramanian, P., Yatsynovich, Y. V., Jacobs, D. M., Chilbert, M. R., Sharma, U. C., Ito, F., Feuerstein, S. G., Stefanovic, F., Switzer, B., Hicar, M. D., Curtis, A. B., Spangenthal, E. J., Dy, G. K., Ernstoff, M. S., Vachhani, P., Page, B. J., Agrawal, N., Khunger, A., \u2026 Schentag, J. J. (2021). Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis. Journal for Immunotherapy of Cancer, 9(6), Article e002553. https:\/\/doi.org\/10.1136\/jitc-2021-002553","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10038_CR90","doi-asserted-by":"publisher","unstructured":"Tomsitz, D., Grabmaier, U., Spiro, J., Nicolai, L., French, L.E., Massberg, S., Heinzerling, L. (2025). Optimized monitoring for immune checkpoint inhibitor induced myocarditis using high-sensitivity troponin-T. European Journal of Cancer, 216, 115186. https:\/\/doi.org\/10.1016\/j.ejca.2024.115186. Epub 2024 Dec 15. PMID: 39708617.","DOI":"10.1016\/j.ejca.2024.115186"},{"issue":"18","key":"10038_CR91","doi-asserted-by":"publisher","DOI":"10.15420\/ecr.2022.63.PMID:37405348;PMCID:PMC10316349","volume":"21","author":"DG Gent","year":"2023","unstructured":"Gent, D. G., & Rebecca, D. (2023). The 2022 european society of cardiology cardio-oncology guidelines in focus. European Cardiology, 21(18), Article e16. https:\/\/doi.org\/10.15420\/ecr.2022.63.PMID:37405348;PMCID:PMC10316349","journal-title":"European Cardiology"},{"key":"10038_CR92","doi-asserted-by":"publisher","unstructured":"Caforio, A.L., Pankuweit, S., Arbustini, E., Basso, C., Gimeno-Blanes, J., Felix, S.B., Fu, M., Heli\u00f6, T., Heymans, S., Jahns, R., Klingel, K., Linhart, A., Maisch, B., McKenna, W., Mogensen, J., Pinto, Y.M., Ristic, A., Schultheiss, H.P., Seggewiss, H., Tavazzi, L., Thiene, G., Yilmaz, A., Charron, P., Elliott, P.M. European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. (2013). Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal 34(33),2636\u201348, 2648a-2648d. https:\/\/doi.org\/10.1093\/eurheartj\/eht210. Epub 2013 Jul 3. PMID: 23824828","DOI":"10.1093\/eurheartj\/eht210"},{"key":"10038_CR93","doi-asserted-by":"publisher","unstructured":"Ammirati, E., Frigerio, M., Adler, E. D., Basso, C., Birnie, D. H., Brambatti, M., Friedrich, M. G., Klingel, K., Lehtonen, J., Moslehi, J. J., Pedrotti, P., Rimoldi, O. E., Schultheiss, H. P., Tsch\u00f6pe, C., Cooper, L. T. Jr., & Camici, P. G. (2020). Management of acute myocarditis and chronic inflammatory cardiomyopathy: An expert consensus document. Circulation: Heart Failure, 13(11), e007405. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.120.007405","DOI":"10.1161\/CIRCHEARTFAILURE.120.007405"},{"key":"10038_CR94","doi-asserted-by":"publisher","first-page":"107211","DOI":"10.1016\/j.carpath.2020.107211","volume":"47","author":"DV Balanescu","year":"2020","unstructured":"Balanescu, D. V., Donisan, T., Palaskas, N., Lopez-Mattei, J., Kim, P. Y., Buja, L. M., McNamara, D. M., Kobashigawa, J. A., Durand, J.-B., & Iliescu, C. A. (2020). Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapy. Cardiovascular Pathology, 47, 107211. https:\/\/doi.org\/10.1016\/j.carpath.2020.107211","journal-title":"Cardiovascular Pathology"},{"issue":"16_suppl","key":"10038_CR95","doi-asserted-by":"publisher","first-page":"TPS2680","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS2680","volume":"41","author":"KL Reynolds","year":"2023","unstructured":"Reynolds, K. L., Zlotoff, D. A., Mooradian, M., Zubiri, L., Ridker, P., & Neilan, T. G. (2023). Abatacept for immune checkpoint inhibitor associated myocarditis (ATRIUM): Phase 3, investigator-initiated, randomized, placebo-controlled study to evaluate the efficacy and safety of abatacept compared to placebo in hospitalized patients with immune checkpoint inhibitor associated myocarditis. JCO, 41(16_suppl), TPS2680\u2013TPS2680. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS2680","journal-title":"JCO"},{"issue":"24","key":"10038_CR96","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMc1901677","volume":"380","author":"J-E Salem","year":"2019","unstructured":"Salem, J.-E., Allenbach, Y., Vozy, A., Brechot, N., Johnson, D. B., Moslehi, J. J., & Kerneis, M. (2019). Abatacept for severe immune checkpoint inhibitor\u2013associated myocarditis. The New England Journal of Medicine, 380(24), 2377\u20132379. https:\/\/doi.org\/10.1056\/NEJMc1901677","journal-title":"The New England Journal of Medicine"},{"key":"10038_CR97","doi-asserted-by":"publisher","unstructured":"Lyon, A.R., Yousaf, N., Battisti NML, Moslehi J, Larkin J. (2018) Immune checkpoint inhibitors and cardiovascular toxicity. Published online September 1,. https:\/\/doi.org\/10.1016\/S1470-2045(18)30457-1","DOI":"10.1016\/S1470-2045(18)30457-1"},{"issue":"10","key":"10038_CR98","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","volume":"15","author":"JC Plana","year":"2014","unstructured":"Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., Ganame, J., Sebag, I. A., Agler, D. A., Badano, L. P., Banchs, J., Cardinale, D., Carver, J., Cerqueira, M., DeCara, J. M., Edvardsen, T., Flamm, S. D., Force, T., Griffin, B. P., \u2026 Lancellotti, P. (2014). Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal \u2013\u00a0Cardiovascular Imaging, 15(10), 1063\u20131093. https:\/\/doi.org\/10.1093\/ehjci\/jeu192","journal-title":"European Heart Journal \u2013\u00a0Cardiovascular Imaging"},{"key":"10038_CR99","doi-asserted-by":"publisher","unstructured":"Trontzas, I.P., Vathiotis, I.A., Kyriakoulis, K.G., Sofianidi, A., Spyropoulou, Z., Charpidou, A., Kotteas, E.A., Syrigos, K.N.; ImmunoTTS Collaborative Group (2023) Takotsubo cardiomyopathy in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-summary of included cases. Cancers (Basel) 15(9):2637. https:\/\/doi.org\/10.3390\/cancers15092637. PMID: 37174104; PMCID: PMC10177389.","DOI":"10.3390\/cancers15092637"},{"issue":"2","key":"10038_CR100","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jaccao.2021.02.005.PMID:34396344;PMCID:PMC8352182","volume":"3","author":"M Serzan","year":"2021","unstructured":"Serzan, M., Rapisuwon, S., Krishnan, J., Chang, I. C., & Barac, A. (2021). Takotsubo cardiomyopathy associated with checkpoint inhibitor therapy: Endomyocardial biopsy provides pathological insights to dual diseases. JACC CardioOncol., 3(2), 330\u2013334. https:\/\/doi.org\/10.1016\/j.jaccao.2021.02.005.PMID:34396344;PMCID:PMC8352182","journal-title":"JACC CardioOncol."},{"key":"10038_CR101","doi-asserted-by":"publisher","unstructured":"Zhang, L., Jones-O\u2019Connor, M., Awadalla, M., Zlotoff, D. A., Thavendiranathan, P., Groarke, J. D., Villani, A.-C., Lyon, A. R., & Neilan, T. G. (2019). Cardiotoxicity of immune checkpoint inhibitors. Current Treatment Options in Cardiovascular Medicine, 21(32). https:\/\/doi.org\/10.1007\/s11936-019-0731-6","DOI":"10.1007\/s11936-019-0731-6"},{"issue":"6","key":"10038_CR102","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"CW Yancy","year":"2017","unstructured":"Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., Hollenberg, S. M., Lindenfeld, J., Masoudi, F. A., McBride, P. E., Peterson, P. N., Stevenson, L. W., & Westlake, C. (2017). 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. Journal of the American College of Cardiology, 70(6), 776\u2013803. https:\/\/doi.org\/10.1016\/j.jacc.2017.04.025","journal-title":"Journal of the American College of Cardiology"},{"issue":"3","key":"10038_CR103","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.jaccao.2024.03.010","volume":"6","author":"LL Taylor","year":"2024","unstructured":"Taylor, L. L., Hong, A. S., Hahm, K., Kim, D., Smith-Morris, C., & Zaha, V. G. (2024). Health literacy, individual and community engagement, and cardiovascular risks and disparities. JACC CardioOncol., 6(3), 363\u2013380. https:\/\/doi.org\/10.1016\/j.jaccao.2024.03.010","journal-title":"JACC CardioOncol."},{"issue":"3","key":"10038_CR104","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s12094-018-1927-1","volume":"21","author":"V Chung","year":"2019","unstructured":"Chung, V., Kos, F. J., Hardwick, N., Yuan, Y., Chao, J., Li, D., Waisman, J., Li, M., Zurcher, K., Frankel, P., & Diamond, D. J. (2019). Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers. Clinical and Translational Oncology, 21(3), 363\u2013372. https:\/\/doi.org\/10.1007\/s12094-018-1927-1","journal-title":"Clinical and Translational Oncology"},{"key":"10038_CR105","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/EDBK_238691","volume":"39","author":"B Santomasso","year":"2019","unstructured":"Santomasso, B., Bachier, C., Westin, J., Rezvani, K., & Shpall, E. J. (2019). The other side of CAR T-cell therapy: Cytokine release syndrome, neurologic toxicity, and financial burden. American Society of Clinical Oncology Educational Book, 39, 433\u2013444. https:\/\/doi.org\/10.1200\/EDBK_238691","journal-title":"American Society of Clinical Oncology Educational Book"},{"key":"10038_CR106","doi-asserted-by":"publisher","unstructured":"Yang, H., Huang, R., Zhang, P., Liu, Y., Liu, Z., He, J., & Peng, X. (2024). Association between statin use and immune-related adverse events in patients treated with immune checkpoint inhibitors: Analysis of the FAERS database. Frontiers in Immunology, 15, 1439231. https:\/\/doi.org\/10.3389\/fimmu.2024.1439231","DOI":"10.3389\/fimmu.2024.1439231"},{"issue":"18","key":"10038_CR107","doi-asserted-by":"publisher","first-page":"e018403","DOI":"10.1161\/JAHA.120.018403","volume":"9","author":"J Alexandre","year":"2020","unstructured":"Alexandre, J., Cautela, J., Ederhy, S., Damaj, G. L., Salem, J.-E., Barlesi, F., Farnault, L., Charbonnier, A., Mirabel, M., Champiat, S., Cohen-Solal, A., Cohen, A., Dolladille, C., & Thuny, F. (2020). Cardiovascular toxicity related to cancer treatment: A pragmatic approach to the American and European cardio-oncology guidelines. Journal of the American Heart Association, 9(18), e018403. https:\/\/doi.org\/10.1161\/JAHA.120.018403","journal-title":"Journal of the American Heart Association"},{"issue":"10124","key":"10038_CR108","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi, J. J., Salem, J. E., Sosman, J. A., Lebrun-Vignes, B., & Johnson, D. B. (2018). Rapid increase in reporting of fatal immune checkpoint inhibitor associated myocarditis. Lancet, 391(10124), 933. https:\/\/doi.org\/10.1016\/S0140-6736(18)30533-6","journal-title":"Lancet"},{"issue":"R2","key":"10038_CR109","doi-asserted-by":"publisher","first-page":"R186","DOI":"10.1093\/hmg\/ddaa137","volume":"29","author":"JA Castrillon","year":"2020","unstructured":"Castrillon, J. A., Eng, C., & Cheng, F. (2020). Pharmacogenomics for immunotherapy and immune-related cardiotoxicity. Human Molecular Genetics, 29(R2), R186\u2013R196. https:\/\/doi.org\/10.1093\/hmg\/ddaa137","journal-title":"Human Molecular Genetics"},{"issue":"2","key":"10038_CR110","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","volume":"31","author":"G Curigliano","year":"2019","unstructured":"Curigliano, G., Lenihan, D., Fradley, M., Ganatra, S., Barac, A., Blaes, A., Herrmann, J., Porter, C., Lyon, A. R., Lancellotti, P., Patel, A., DeCara, J., Mitchell, J., Harrison, E., Moslehi, J., Witteles, R., Calabro, M. G., Orecchia, R., de Azambuja, E., \u2026 Jordan, K. (2019). Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Annals of Oncology, 31(2), 171\u2013190. https:\/\/doi.org\/10.1016\/j.annonc.2019.10.023","journal-title":"Annals of Oncology"},{"key":"10038_CR111","doi-asserted-by":"publisher","unstructured":"Delombaerde, D., Vervloet, D., Franssen, C., Croes, L., Gremonprez, F., Prenen, H., Peeters, M., & Vulsteke, C. (2021). Clinical implications of isolated troponinemia following immune checkpoint inhibitor therapy. ESMO Open, 6(4), 100216. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100216","DOI":"10.1016\/j.esmoop.2021.100216"},{"issue":"17","key":"10038_CR112","doi-asserted-by":"publisher","first-page":"4577","DOI":"10.3390\/cancers13174577","volume":"13","author":"Y Shiravand","year":"2021","unstructured":"Shiravand, Y., Khodadadi, F., Kashani, S. M. A., Hosseini-Fard, S. R., Hosseini, S., Sadeghirad, H., Ladwa, R., O\u2019Byrne, K., & Kulasinghe, A. (2021). Immune checkpoint inhibitors in cancer therapy. Cancers, 13(17), 4577. https:\/\/doi.org\/10.3390\/cancers13174577","journal-title":"Cancers"},{"key":"10038_CR113","doi-asserted-by":"publisher","first-page":"1167975","DOI":"10.3389\/fimmu.2023.1167975","volume":"14","author":"Q Yin","year":"2023","unstructured":"Yin, Q., Wu, L., Han, L., Li, Y., Zhang, H., Guo, W., & Wang, J. (2023). Immune-related adverse events of immune checkpoint inhibitors: A review. Frontiers in Immunology, 14, 1167975. https:\/\/doi.org\/10.3389\/fimmu.2023.1167975","journal-title":"Frontiers in Immunology"},{"issue":"17","key":"10038_CR114","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., Hallmeyer, S., Holter Chakrabarty, J., Leighl, N. B., Mammen, J. S., McDermott, D. F., Naing, A., Nastoupil, L. J., Phillips, T., Porter, L. D., \u2026 Thompson, J. . A. . (2018). Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology, 36(17), 1714\u20131768. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385","journal-title":"Journal of Clinical Oncology"},{"issue":"6371","key":"10038_CR115","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2017","unstructured":"Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Hoffman, K., Wei, S. C., Cogdill, A. P., Zhao, L., Hudgens, C. W., Hutchinson, D. S., Manzo, T., Petaccia de Macedo, M., Cotechini, T., Kumar, T., Chen, W. S., Reddy, S. M., \u2026 Wargo, J. A. (2017). Gut microbiome modulates response to anti\u2013PD-1 immunotherapy in melanoma patients. Science, 359(6371), 97\u2013103. https:\/\/doi.org\/10.1126\/science.aan4236","journal-title":"Science"},{"issue":"6264","key":"10038_CR116","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1126\/science.aac4255","volume":"350","author":"A Sivan","year":"2015","unstructured":"Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Lei, Y. M., Jabri, B., Alegre, M. L., Chang, E. B., & Gajewski, T. F. (2015). Commensal Bifidobacterium promotes antitumor immunity and facilitates anti\u2013PD-L1 efficacy. Science, 350(6264), 1084\u20131089. https:\/\/doi.org\/10.1126\/science.aac4255","journal-title":"Science"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-025-10038-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12012-025-10038-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-025-10038-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T07:16:50Z","timestamp":1757229410000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12012-025-10038-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,13]]},"references-count":116,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10038"],"URL":"https:\/\/doi.org\/10.1007\/s12012-025-10038-y","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,13]]},"assertion":[{"value":"14 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical Trial Number"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}